deepa328
Axonics Sacral Neurouromodulation
Axonics, Inc. received FDA approval on November 19, 2019, for its Axonics Sacral Neurostimulator (SNM).
AxonicsSacralNeurostimulator (SNM) offers several advanced features to treat #urinaryretention and the symptoms associated with an #overactivebladder. Axonics SNM system is designed to last in the body for at least a period of 15 years, allowing more significant symptom reductions for overactive bladder, bowel incontinence, and urinary retention.
However, the Axonics SNM system is expected to face major competition from BInterstim II devices. Similarly, other leading players in the domain such as Nuvectra, Cogentix Medical, Inc., and others are also strengthening their position in the #market.
Learn about the latest development in the Sacral Nerve Stimulation market and how it is expected to rise in the coming years, at: www.delveinsight.com/report-store/sacral-nerve-stimulatio...
Axonics Sacral Neurouromodulation
Axonics, Inc. received FDA approval on November 19, 2019, for its Axonics Sacral Neurostimulator (SNM).
AxonicsSacralNeurostimulator (SNM) offers several advanced features to treat #urinaryretention and the symptoms associated with an #overactivebladder. Axonics SNM system is designed to last in the body for at least a period of 15 years, allowing more significant symptom reductions for overactive bladder, bowel incontinence, and urinary retention.
However, the Axonics SNM system is expected to face major competition from BInterstim II devices. Similarly, other leading players in the domain such as Nuvectra, Cogentix Medical, Inc., and others are also strengthening their position in the #market.
Learn about the latest development in the Sacral Nerve Stimulation market and how it is expected to rise in the coming years, at: www.delveinsight.com/report-store/sacral-nerve-stimulatio...